Deterioration of plasticity and metabolic homeostasis in the brain of the UCD-T2DM rat model of naturally occurring type-2 diabetes

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 9, 2014, Pages 1313-1323

  Agrawal, Rahul ^a   Zhuang, Yumei ^b   Cummings, Bethany P ^c   Stanhope, Kimber L ^c   Graham, James L ^c   Havel, Peter J ^c   Gomez Pinilla, Fernando ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dietary energy restriction; Energy homeostasis; Insulin signaling; Liraglutide; Plasticity; Type 2 diabetes

Indexed keywords

4 HYDROXYNONENAL; ADENYLATE KINASE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; GLUCOSE; INSULIN; INSULIN RECEPTOR; LIRAGLUTIDE; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SIRTUIN 1; TRIACYLGLYCEROL; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; SIRTUIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DETERIORATION; ENZYME PHOSPHORYLATION; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; INSULIN RESISTANCE; MALE; NERVE CELL PLASTICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; BODY WEIGHT; BRAIN; DIET RESTRICTION; ENERGY METABOLISM; HIPPOCAMPUS; IMMUNOBLOTTING; INSULIN SENSITIVITY; PROTEIN EXPRESSION; RAT MODEL; SYNAPSE; TREATMENT OUTCOME;

DIETARY ENERGY RESTRICTION; ENERGY HOMEOSTASIS; INSULIN SIGNALING; LIRAGLUTIDE; PLASTICITY; TYPE-2 DIABETES;

ALDEHYDES; ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BRAIN; CROSSES, GENETIC; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; GLUCAGON-LIKE PEPTIDE 1; HIPPOCAMPUS; HOMEOSTASIS; HYPOGLYCEMIC AGENTS; IMMUNOBLOTTING; INSULIN RESISTANCE; MALE; NEURONAL PLASTICITY; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; RECEPTOR, INSULIN;

EID: 84903439354     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.05.007     Document Type: Article

References (60)

1. Moran C., Phan T.G., Chen J., Blizzard L., Beare R., Venn A., Münch G., Wood A.G., Forbes J., Greenaway T.M., Pearson S., Srikanth V. Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care 2013, 36:4036-4042.
2. Reijmer Y.D., Brundel M., de Bresser J., Kappelle L.J., Leemans A., Biessels G.J., U.V.C.I.S.Group Microstructural white matter abnormalities and cognitive functioning in type 2 diabetes: a diffusion tensor imaging study. Diabetes Care 2013, 36:137-144.
3. Agrawal R., Gomez-Pinilla F. 'Metabolic syndrome' in the brain: deficiency in omega-3 fatty acid exacerbates dysfunctions in insulin receptor signalling and cognition. J. Physiol. 2012, 590:2485-2499.
4. Cummings B.P., Digitale E.K., Stanhope K.L., Graham J.L., Baskin D.G., Reed B.J., Sweet I.R., Griffen S.C., Havel P.J. Development and characterization of a novel rat model of type 2 diabetes mellitus: the UC Davis type 2 diabetes mellitus UCD-T2DM rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 295:R1782-R1793.
5. Lu H., Koshkin V., Allister E.M., Gyulkhandanyan A.V., Wheeler M.B. Molecular and metabolic evidence for mitochondrial defects associated with beta-cell dysfunction in a mouse model of type 2 diabetes. Diabetes 2010, 59:448-459.
6. Szendroedi J., Phielix E., Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2012, 8:92-103.
7. Cheng Z., Tseng Y., White M.F. Insulin signaling meets mitochondria in metabolism. Trends Endocrinol. Metab. 2010, 21:589-598.
8. Kim J.A., Wei Y., Sowers J.R. Role of mitochondrial dysfunction in insulin resistance. Circ. Res. 2008, 102:401-414.
9. Ventura-Clapier R., Garnier A., Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc. Res. 2008, 79:208-217.
10. Campbell C.T., Kolesar J.E., Kaufman B.A. Mitochondrial transcription factor A regulates mitochondrial transcription initiation, DNA packaging, and genome copy number. Biochim. Biophys. Acta 2012, 1819:921-929.
11. Cheng A., Wan R., Yang J.L., Kamimura N., Son T.G., Ouyang X., Luo Y., Okun E., Mattson M.P. Involvement of PGC-1α in the formation and maintenance of neuronal dendritic spines. Nat. Commun. 2012, 3:1250.
12. Gomez-Pinilla F., Vaynman S., Ying Z. Brain-derived neurotrophic factor functions as a metabotrophin to mediate the effects of exercise on cognition. Eur. J. Neurosci. 2008, 28:2278-2287.
13. Yamanaka M., Tsuchida A., Nakagawa T., Nonomura T., Ono-Kishino M., Sugaru E., Noguchi H., Taiji M. Brain-derived neurotrophic factor enhances glucose utilization in peripheral tissues of diabetic mice. Diabetes Obes. Metab. 2007, 9:59-64.
14. Horowitz M., Flint A., Jones K.L., Hindsberger C., Rasmussen M.F., Kapitza C., Doran S., Jax T., Zdravkovic M., Chapman I.M. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res. Clin. Pract. 2012, 97:258-266.
15. Duivenvoorde L.P., van Schothorst E.M., Bunschoten A., Keijer J. Dietary restriction of mice on a high-fat diet induces substrate efficiency and improves metabolic health. J. Mol. Endocrinol. 2011, 47:81-97.
16. Hunter K., Hölscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012, 13:33.
17. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2009, 5:262-269.
18. Flint A., Kapitza C., Hindsberger C., Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv. Ther. 2011, 28:213-226.
19. Degn K.B., Juhl C.B., Sturis J., Jakobsen G., Brock B., Chandramouli V., Rungby J., Landau B.R., Schmitz O. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004, 53:1187-1194.
20. Perry T., Lahiri D.K., Chen D., Zhou J., Shaw K.T., Egan J.M., Greig N.H. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 2002, 300:958-966.
21. Bomfim T.R., Forny-Germano L., Sathler L.B., Brito-Moreira J., Houzel J.C., Decker H., Silverman M.A., Kazi H., Melo H.M., McClean P.L., Holscher C., Arnold S.E., Talbot K., Klein W.L., Munoz D.P., Ferreira S.T., De Felice F.G. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers. J. Clin. Invest. 2012, 122:1339-1353.
22. McClean P.L., Parthsarathy V., Faivre E., Hölscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 2011, 31:6587-6594.
23. Li Y., Perry T., Kindy M.S., Harvey B.K., Tweedie D., Holloway H.W., Powers K., Shen H., Egan J.M., Sambamurti K., Brossi A., Lahiri D.K., Mattson M.P., Hoffer B.J., Wang Y., Greig N.H. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1285-1290.
24. López-Lluch G., Hunt N., Jones B., Zhu M., Jamieson H., Hilmer S., Cascajo M.V., Allard J., Ingram D.K., Navas P., de Cabo R. Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1768-1773.
25. Maalouf M., Rho J.M., Mattson M.P. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res. Rev. 2009, 59:293-315.
26. Griffen S.C., Wang J., German M.S. A genetic defect in beta-cell gene expression segregates independently from the fa locus in the ZDF rat. Diabetes 2001, 50:63-68.
27. Cummings B.P., Stanhope K.L., Graham J.L., Baskin D.G., Griffen S.C., Nilsson C., Sams A., Knudsen L.B., Raun K., Havel P.J. Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. Diabetes 2010, 59:2653-2661.
28. Cummings B.P., Strader A.D., Stanhope K.L., Graham J.L., Lee J., Raybould H.E., Baskin D.G., Havel P.J. Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology 2010, 138:2437-2446. (2446.e2431).
29. Cummings B.P., Bettaieb A., Graham J.L., Stanhope K.L., Kowala M., Haj F.G., Chouinard M.L., Havel P.J. Vertical sleeve gastrectomy improves glucose and lipid metabolism and delays diabetes onset in UCD-T2DM rats. Endocrinology 2012, 153:3620-3632.
30. Bergeron R., Yao J., Woods J.W., Zycband E.I., Liu C., Li Z., Adams A., Berger J.P., Zhang B.B., Moller D.E., Doebber T.W. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: a comparison with PPAR gamma agonism. Endocrinology 2006, 147:4252-4262.
31. Peterson G.E., Pollom R.D. Liraglutide in clinical practice: dosing, safety and efficacy. Int. J. Clin. Pract. Suppl. 2010, 35-43.
32. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22:659-661.
33. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
34. Chen S.D., Yang D.I., Lin T.K., Shaw F.Z., Liou C.W., Chuang Y.C. Roles of oxidative stress, apoptosis, PGC-1α and mitochondrial biogenesis in cerebral ischemia. Int. J. Mol. Sci. 2011, 12:7199-7215.
35. Valle I., Alvarez-Barrientos A., Arza E., Lamas S., Monsalve M. PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc. Res. 2005, 66:562-573.
36. Hiona A., Leeuwenburgh C. Effects of age and caloric restriction on brain neuronal cell death/survival. Ann. N. Y. Acad. Sci. 2004, 1019:96-105.
37. Halagappa V.K., Guo Z., Pearson M., Matsuoka Y., Cutler R.G., Laferla F.M., Mattson M.P. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 2007, 26:212-220.
38. Starai V.J., Celic I., Cole R.N., Boeke J.D., Escalante-Semerena J.C. Sir2-dependent activation of acetyl-CoA synthetase by deacetylation of active lysine. Science 2002, 298:2390-2392.
39. Hallows W.C., Lee S., Denu J.M. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:10230-10235.
40. Hernández-Fonseca J.P., Rincón J., Pedreañez A., Viera N., Arcaya J.L., Carrizo E., Mosquera J. Structural and ultrastructural analysis of cerebral cortex, cerebellum, and hypothalamus from diabetic rats. Exp. Diabetes Res. 2009, 2009:329632.
41. Last D., Alsop D.C., Abduljalil A.M., Marquis R.P., de Bazelaire C., Hu K., Cavallerano J., Novak V. Global and regional effects of type 2 diabetes on brain tissue volumes and cerebral vasoreactivity. Diabetes Care 2007, 30:1193-1199.
42. Abdul-Rahman O., Sasvari-Szekely M., Ver A., Rosta K., Szasz B.K., Kereszturi E., Keszler G. Altered gene expression profiles in the hippocampus and prefrontal cortex of type 2 diabetic rats. BMC Genomics 2012, 13:81.
43. Tweedie D., Rachmany L., Rubovitch V., Lehrmann E., Zhang Y., Becker K.G., Perez E., Miller J., Hoffer B.J., Greig N.H., Pick C.G. Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Exp. Neurol. 2013, 239:170-182.
44. Long-Smith C.M., Manning S., McClean P.L., Coakley M.F., O'Halloran D.J., Holscher C., O'Neill C. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromolecular Med. 2013, 15:102-114.
45. Swarbrick M.M., Havel P.J. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab. Syndr. Relat. Disord. 2008, 6:87-102.
46. Roy Chowdhury S.K., Smith D.R., Saleh A., Schapansky J., Marquez A., Gomes S., Akude E., Morrow D., Calcutt N.A., Fernyhough P. Impaired adenosine monophosphate-activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes. Brain 2012, 135:1751-1766.
47. Rodgers J.T., Lerin C., Gerhart-Hines Z., Puigserver P. Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett. 2008, 582:46-53.
48. Agrawal R., Tyagi E., Vergnes L., Reue K., Gomez-Pinilla F. Coupling energy homeostasis with a mechanism to support plasticity in brain trauma. Biochim. Biophys. Acta 2014, 1842:535-546.
49. Liu J., Head E., Gharib A.M., Yuan W., Ingersoll R.T., Hagen T.M., Cotman C.W., Ames B.N. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:2356-2361.
50. Burkhalter J., Fiumelli H., Allaman I., Chatton J.Y., Martin J.L. Brain-derived neurotrophic factor stimulates energy metabolism in developing cortical neurons. J. Neurosci. 2003, 23:8212-8220.
51. Herzig S., Long F., Jhala U.S., Hedrick S., Quinn R., Bauer A., Rudolph D., Schutz G., Yoon C., Puigserver P., Spiegelman B., Montminy M. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 2001, 413:179-183.
52. Gao J., Wang W.Y., Mao Y.W., Gräff J., Guan J.S., Pan L., Mak G., Kim D., Su S.C., Tsai L.H. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 2010, 466:1105-1109.
53. Michán S., Li Y., Chou M.M., Parrella E., Ge H., Long J.M., Allard J.S., Lewis K., Miller M., Xu W., Mervis R.F., Chen J., Guerin K.I., Smith L.E., McBurney M.W., Sinclair D.A., Baudry M., de Cabo R., Longo V.D. SIRT1 is essential for normal cognitive function and synaptic plasticity. J. Neurosci. 2010, 30:9695-9707.
54. Nemoto S., Fergusson M.M., Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J. Biol. Chem. 2005, 280:16456-16460.
55. Rodgers J.T., Lerin C., Haas W., Gygi S.P., Spiegelman B.M., Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005, 434:113-118.
56. Rafaeloff-Phail R., Ding L., Conner L., Yeh W.K., McClure D., Guo H., Emerson K., Brooks H. Biochemical regulation of mammalian AMP-activated protein kinase activity by NAD and NADH. J. Biol. Chem. 2004, 279:52934-52939.
57. Houtkooper R.H., Pirinen E., Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 2012, 13:225-238.
58. Hirschey M.D., Shimazu T., Capra J.A., Pollard K.S., Verdin E. SIRT1 and SIRT3 deacetylate homologous substrates: AceCS1,2 and HMGCS1,2. Aging (Albany NY) 2011, 3:635-642.
59. Pfluger P.T., Herranz D., Velasco-Miguel S., Serrano M., Tschöp M.H. Sirt1 protects against high-fat diet-induced metabolic damage. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:9793-9798.
60. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.